The Sars-Cov-2 Pandemic and the Brave New Digital World of Environmental Enrichment to Prevent Brain Aging and Cognitive Decline.
Identifieur interne : 000162 ( Main/Exploration ); précédent : 000161; suivant : 000163The Sars-Cov-2 Pandemic and the Brave New Digital World of Environmental Enrichment to Prevent Brain Aging and Cognitive Decline.
Auteurs : H. Hampel [Colombie] ; A. VergalloSource :
- The journal of prevention of Alzheimer's disease [ 2426-0266 ] ; 2020.
Descripteurs français
- KwdFr :
- Betacoronavirus (MeSH), Dysfonctionnement cognitif (prévention et contrôle), Dysfonctionnement cognitif (psychologie), Facteurs de risque (MeSH), Humains (MeSH), Infections à coronavirus (MeSH), Isolement social (psychologie), Maladie d'Alzheimer (prévention et contrôle), Maladie d'Alzheimer (psychologie), Mâle (MeSH), Pandémies (MeSH), Pneumopathie virale (MeSH), Quarantaine (psychologie), Relations interpersonnelles (MeSH), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Technologie (MeSH), Vieillissement (MeSH), Évolution de la maladie (MeSH).
- MESH :
- prévention et contrôle : Dysfonctionnement cognitif, Maladie d'Alzheimer.
- psychologie : Dysfonctionnement cognitif, Isolement social, Maladie d'Alzheimer, Quarantaine.
- Betacoronavirus, Facteurs de risque, Humains, Infections à coronavirus, Mâle, Pandémies, Pneumopathie virale, Relations interpersonnelles, Sujet âgé, Sujet âgé de 80 ans ou plus, Technologie, Vieillissement, Évolution de la maladie.
English descriptors
- KwdEn :
- Aged (MeSH), Aged, 80 and over (MeSH), Aging (MeSH), Alzheimer Disease (prevention & control), Alzheimer Disease (psychology), Betacoronavirus (MeSH), Cognitive Dysfunction (prevention & control), Cognitive Dysfunction (psychology), Coronavirus Infections (MeSH), Disease Progression (MeSH), Humans (MeSH), Interpersonal Relations (MeSH), Male (MeSH), Pandemics (MeSH), Pneumonia, Viral (MeSH), Quarantine (psychology), Risk Factors (MeSH), Social Isolation (psychology), Technology (MeSH).
- MESH :
- prevention & control : Alzheimer Disease, Cognitive Dysfunction.
- psychology : Alzheimer Disease, Cognitive Dysfunction, Quarantine, Social Isolation.
- Aged, Aged, 80 and over, Aging, Betacoronavirus, Coronavirus Infections, Disease Progression, Humans, Interpersonal Relations, Male, Pandemics, Pneumonia, Viral, Risk Factors, Technology.
Abstract
Individuals experiencing brain aging, cognitive decline, and dementia are currently confronted with several more complex challenges due to the current Sars-Cov-2 pandemic as compared to younger and cognitively healthy people. During the first six months of the pandemic, we are experiencing critical issues related to the management of mild cognitive impairment (MCI) and dementia. The evolving, highly contagious global viral spread has created a pressure test of unprecedented proportions for the existing brain health care infrastructure and related services for management, diagnosis, treatment, and prevention. Social distancing and lock-down measures are catalyzing and accelerating a technological paradigm shift, away from a traditional model of brain healthcare focused on late symptomatic disease stages and towards optimized preventive strategies to slow brain aging and increase resilience at preclinical asymptomatic stages. Digital technologies transform global healthcare for accessible equality of opportunities in order to generate better outcomes for brain aging aligned with the paradigm of preventive medicine.
DOI: 10.14283/jpad.2020.39
PubMed: 32920634
PubMed Central: PMC7355512
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Sars-Cov-2 Pandemic and the Brave New Digital World of Environmental Enrichment to Prevent Brain Aging and Cognitive Decline.</title><author><name sortKey="Hampel, H" sort="Hampel, H" uniqKey="Hampel H" first="H" last="Hampel">H. Hampel</name><affiliation wicri:level="1"><nlm:affiliation>Harald Hampel and Andrea Vergallo, Eisai Inc., Neurology Business Group, 100 Tice Blvd, Woodcliff Lake, NJ 07677, USA, Tel: (+1) 201-746-2060 (o) harald_hampel@eisai.com; andrea_vergallo@eisai.com.</nlm:affiliation><country wicri:rule="url">Colombie</country><wicri:regionArea>Harald Hampel and Andrea Vergallo, Eisai Inc., Neurology Business Group, 100 Tice Blvd, Woodcliff Lake, NJ 07677, USA</wicri:regionArea><wicri:noRegion>USA</wicri:noRegion></affiliation></author><author><name sortKey="Vergallo, A" sort="Vergallo, A" uniqKey="Vergallo A" first="A" last="Vergallo">A. Vergallo</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32920634</idno><idno type="pmid">32920634</idno><idno type="doi">10.14283/jpad.2020.39</idno><idno type="pmc">PMC7355512</idno><idno type="wicri:Area/Main/Corpus">000246</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000246</idno><idno type="wicri:Area/Main/Curation">000246</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000246</idno><idno type="wicri:Area/Main/Exploration">000246</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The Sars-Cov-2 Pandemic and the Brave New Digital World of Environmental Enrichment to Prevent Brain Aging and Cognitive Decline.</title><author><name sortKey="Hampel, H" sort="Hampel, H" uniqKey="Hampel H" first="H" last="Hampel">H. Hampel</name><affiliation wicri:level="1"><nlm:affiliation>Harald Hampel and Andrea Vergallo, Eisai Inc., Neurology Business Group, 100 Tice Blvd, Woodcliff Lake, NJ 07677, USA, Tel: (+1) 201-746-2060 (o) harald_hampel@eisai.com; andrea_vergallo@eisai.com.</nlm:affiliation><country wicri:rule="url">Colombie</country><wicri:regionArea>Harald Hampel and Andrea Vergallo, Eisai Inc., Neurology Business Group, 100 Tice Blvd, Woodcliff Lake, NJ 07677, USA</wicri:regionArea><wicri:noRegion>USA</wicri:noRegion></affiliation></author><author><name sortKey="Vergallo, A" sort="Vergallo, A" uniqKey="Vergallo A" first="A" last="Vergallo">A. Vergallo</name></author></analytic><series><title level="j">The journal of prevention of Alzheimer's disease</title><idno type="eISSN">2426-0266</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Aging (MeSH)</term><term>Alzheimer Disease (prevention & control)</term><term>Alzheimer Disease (psychology)</term><term>Betacoronavirus (MeSH)</term><term>Cognitive Dysfunction (prevention & control)</term><term>Cognitive Dysfunction (psychology)</term><term>Coronavirus Infections (MeSH)</term><term>Disease Progression (MeSH)</term><term>Humans (MeSH)</term><term>Interpersonal Relations (MeSH)</term><term>Male (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (MeSH)</term><term>Quarantine (psychology)</term><term>Risk Factors (MeSH)</term><term>Social Isolation (psychology)</term><term>Technology (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Betacoronavirus (MeSH)</term><term>Dysfonctionnement cognitif (prévention et contrôle)</term><term>Dysfonctionnement cognitif (psychologie)</term><term>Facteurs de risque (MeSH)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (MeSH)</term><term>Isolement social (psychologie)</term><term>Maladie d'Alzheimer (prévention et contrôle)</term><term>Maladie d'Alzheimer (psychologie)</term><term>Mâle (MeSH)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (MeSH)</term><term>Quarantaine (psychologie)</term><term>Relations interpersonnelles (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Technologie (MeSH)</term><term>Vieillissement (MeSH)</term><term>Évolution de la maladie (MeSH)</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Alzheimer Disease</term><term>Cognitive Dysfunction</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Dysfonctionnement cognitif</term><term>Maladie d'Alzheimer</term></keywords><keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Dysfonctionnement cognitif</term><term>Isolement social</term><term>Maladie d'Alzheimer</term><term>Quarantaine</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Alzheimer Disease</term><term>Cognitive Dysfunction</term><term>Quarantine</term><term>Social Isolation</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Aging</term><term>Betacoronavirus</term><term>Coronavirus Infections</term><term>Disease Progression</term><term>Humans</term><term>Interpersonal Relations</term><term>Male</term><term>Pandemics</term><term>Pneumonia, Viral</term><term>Risk Factors</term><term>Technology</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Betacoronavirus</term><term>Facteurs de risque</term><term>Humains</term><term>Infections à coronavirus</term><term>Mâle</term><term>Pandémies</term><term>Pneumopathie virale</term><term>Relations interpersonnelles</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Technologie</term><term>Vieillissement</term><term>Évolution de la maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Individuals experiencing brain aging, cognitive decline, and dementia are currently confronted with several more complex challenges due to the current Sars-Cov-2 pandemic as compared to younger and cognitively healthy people. During the first six months of the pandemic, we are experiencing critical issues related to the management of mild cognitive impairment (MCI) and dementia. The evolving, highly contagious global viral spread has created a pressure test of unprecedented proportions for the existing brain health care infrastructure and related services for management, diagnosis, treatment, and prevention. Social distancing and lock-down measures are catalyzing and accelerating a technological paradigm shift, away from a traditional model of brain healthcare focused on late symptomatic disease stages and towards optimized preventive strategies to slow brain aging and increase resilience at preclinical asymptomatic stages. Digital technologies transform global healthcare for accessible equality of opportunities in order to generate better outcomes for brain aging aligned with the paradigm of preventive medicine.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32920634</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2426-0266</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>4</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>The journal of prevention of Alzheimer's disease</Title><ISOAbbreviation>J Prev Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>The Sars-Cov-2 Pandemic and the Brave New Digital World of Environmental Enrichment to Prevent Brain Aging and Cognitive Decline.</ArticleTitle><Pagination><MedlinePgn>294-298</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.14283/jpad.2020.39</ELocationID><Abstract><AbstractText>Individuals experiencing brain aging, cognitive decline, and dementia are currently confronted with several more complex challenges due to the current Sars-Cov-2 pandemic as compared to younger and cognitively healthy people. During the first six months of the pandemic, we are experiencing critical issues related to the management of mild cognitive impairment (MCI) and dementia. The evolving, highly contagious global viral spread has created a pressure test of unprecedented proportions for the existing brain health care infrastructure and related services for management, diagnosis, treatment, and prevention. Social distancing and lock-down measures are catalyzing and accelerating a technological paradigm shift, away from a traditional model of brain healthcare focused on late symptomatic disease stages and towards optimized preventive strategies to slow brain aging and increase resilience at preclinical asymptomatic stages. Digital technologies transform global healthcare for accessible equality of opportunities in order to generate better outcomes for brain aging aligned with the paradigm of preventive medicine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Harald Hampel and Andrea Vergallo, Eisai Inc., Neurology Business Group, 100 Tice Blvd, Woodcliff Lake, NJ 07677, USA, Tel: (+1) 201-746-2060 (o) harald_hampel@eisai.com; andrea_vergallo@eisai.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vergallo</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Prev Alzheimers Dis</MedlineTA><NlmUniqueID>101638820</NlmUniqueID><ISSNLinking>2274-5807</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="Y">Coronavirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007398" MajorTopicYN="Y">Interpersonal Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="Y">Pneumonia, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011790" MajorTopicYN="N">Quarantine</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012934" MajorTopicYN="N">Social Isolation</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013672" MajorTopicYN="N">Technology</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Alzheimer’s disease</Keyword><Keyword MajorTopicYN="Y">Brain aging</Keyword><Keyword MajorTopicYN="Y">enviromental enrichment</Keyword><Keyword MajorTopicYN="Y">social distancing</Keyword></KeywordList><CoiStatement>HH is an employee of Eisai Inc. and serves as Senior Associate Editor for the Journal Alzheimer’s and Dementia and does not receive any fees or honoraria since May 2019; before May 2019 he had received lecture fees from Servier, Biogen and Roche, research grants from Pfizer, Avid, and MSD Avenir (paid to the institution), travel funding from Eisai, Functional Neuromodulation, Axovant, Eli Lilly and company, Takeda and Zinfandel, GE-Healthcare and Oryzon Genomics, consultancy fees from Qynapse, Jung Diagnostics, Cytox Ltd., Axovant, Anavex, Takeda and Zinfandel, GE Healthcare, Oryzon Genomics, and Functional Neuromodulation, and participated in scientific advisory boards of Functional Neuromodulation, Axovant, Eisai, Eli Lilly and company, Cytox Ltd., GE Healthcare, Takeda and Zinfandel, Oryzon Genomics and Roche Diagnostics. He is co-inventor in the following patents as a scientific expert and has received no royalties: • In Vitro Multiparameter Determination Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Patent Number: 8916388; • In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases Patent Number: 8298784; • Neurodegenerative Markers for Psychiatric Conditions Publication Number: 20120196300; • In Vitro Multiparameter Determination Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Publication Number: 20100062463; • In Vitro Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Publication Number: 20100035286; • In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases Publication Number: 20090263822; • In Vitro Method for The Diagnosis of Neurodegenerative Diseases Patent Number: 7547553; • CSF Diagnostic in Vitro Method for Diagnosis of Dementias and Neuroinflammatory Diseases Publication Number: 20080206797; • In Vitro Method for The Diagnosis of Neurodegenerative Diseases Publication Number: 20080199966; • Neurodegenerative Markers for Psychiatric Conditions Publication Number: 20080131921; AV is an employee of Eisai Inc. He does not receive any fees or honoraria since November 2019. Before November 2019, he had received lecture honoraria from Roche, MagQu LLC, and Servier.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>13</Day><Hour>20</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32920634</ArticleId><ArticleId IdType="doi">10.14283/jpad.2020.39</ArticleId><ArticleId IdType="pmc">PMC7355512</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet Neurol. 2012 Nov;11(11):1006-12</Citation><ArticleIdList><ArticleId IdType="pubmed">23079557</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement (Amst). 2015 Nov 14;1(4):521-32</Citation><ArticleIdList><ArticleId IdType="pubmed">27239530</ArticleId></ArticleIdList></Reference><Reference><Citation>NPJ Digit Med. 2019;2:</Citation><ArticleIdList><ArticleId IdType="pubmed">31119198</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2012 Apr;1252:312-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22524373</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Public Health. 2019 Feb 19;7:22</Citation><ArticleIdList><ArticleId IdType="pubmed">30838194</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2010 Aug;198(8):586-92</Citation><ArticleIdList><ArticleId IdType="pubmed">20699725</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2012 Sep;20(9):806-14</Citation><ArticleIdList><ArticleId IdType="pubmed">21997602</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2020 May 22;368(6493):860-868</Citation><ArticleIdList><ArticleId IdType="pubmed">32291278</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2011;25(1):85-91</Citation><ArticleIdList><ArticleId IdType="pubmed">21335662</ArticleId></ArticleIdList></Reference><Reference><Citation>J Prev Alzheimers Dis. 2020;7(3):171-178</Citation><ArticleIdList><ArticleId IdType="pubmed">32463070</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2020 Jun;288:113028</Citation><ArticleIdList><ArticleId IdType="pubmed">32361337</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Rev. 2007 Jul;87(3):873-904</Citation><ArticleIdList><ArticleId IdType="pubmed">17615391</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2017 May;32(5):564-573</Citation><ArticleIdList><ArticleId IdType="pubmed">27162047</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Med (Lausanne). 2018 Sep 11;5:255</Citation><ArticleIdList><ArticleId IdType="pubmed">30255022</ArticleId></ArticleIdList></Reference><Reference><Citation>J Prev Alzheimers Dis. 2020;7(3):197-198</Citation><ArticleIdList><ArticleId IdType="pubmed">32463074</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2020 May;287:112915</Citation><ArticleIdList><ArticleId IdType="pubmed">32199182</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2005 May 25;25(21):5217-24</Citation><ArticleIdList><ArticleId IdType="pubmed">15917461</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2002 Sep 25;288(12):1475-83</Citation><ArticleIdList><ArticleId IdType="pubmed">12243634</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Psychiatry. 2020 Jun;7(6):547-560</Citation><ArticleIdList><ArticleId IdType="pubmed">32304649</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cogn Sci. 2013 Oct;17(10):502-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24018144</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Aging Neurosci. 2014 Dec 17;6:338</Citation><ArticleIdList><ArticleId IdType="pubmed">25566069</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2017 Mar 28;14(3):e1002269</Citation><ArticleIdList><ArticleId IdType="pubmed">28350796</ArticleId></ArticleIdList></Reference><Reference><Citation>Perspect Psychol Sci. 2018 Jan;13(1):70-87</Citation><ArticleIdList><ArticleId IdType="pubmed">28937910</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2011 Sep;7(5):532-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21889116</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2017 Dec 16;390(10113):2673-2734</Citation><ArticleIdList><ArticleId IdType="pubmed">28735855</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 Feb;64(2):234-40</Citation><ArticleIdList><ArticleId IdType="pubmed">17283291</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Neurol. 2013 Jan;239:28-37</Citation><ArticleIdList><ArticleId IdType="pubmed">23022919</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2012 Feb 8;32(6):1942-52</Citation><ArticleIdList><ArticleId IdType="pubmed">22323707</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2013 Sep 10;3:e304</Citation><ArticleIdList><ArticleId IdType="pubmed">24022509</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Neurol. 2013 Aug;70(8):1074-5</Citation><ArticleIdList><ArticleId IdType="pubmed">23939592</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(1):e29676</Citation><ArticleIdList><ArticleId IdType="pubmed">22253758</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement (N Y). 2018 May 24;4:234-242</Citation><ArticleIdList><ArticleId IdType="pubmed">29955666</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2013 Sep 5;501(7465):97-101</Citation><ArticleIdList><ArticleId IdType="pubmed">24005416</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurol. 2012 May 07;3:73</Citation><ArticleIdList><ArticleId IdType="pubmed">22586419</ArticleId></ArticleIdList></Reference><Reference><Citation>Cyberpsychol Behav Soc Netw. 2016 Sep;19(9):551-6</Citation><ArticleIdList><ArticleId IdType="pubmed">27541746</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2010 Jun;24(6):1667-81</Citation><ArticleIdList><ArticleId IdType="pubmed">20086049</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Colombie</li></country></list><tree><noCountry><name sortKey="Vergallo, A" sort="Vergallo, A" uniqKey="Vergallo A" first="A" last="Vergallo">A. Vergallo</name></noCountry><country name="Colombie"><noRegion><name sortKey="Hampel, H" sort="Hampel, H" uniqKey="Hampel H" first="H" last="Hampel">H. Hampel</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidSeniorV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000162 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000162 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidSeniorV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32920634
|texte= The Sars-Cov-2 Pandemic and the Brave New Digital World of Environmental Enrichment to Prevent Brain Aging and Cognitive Decline.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32920634" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidSeniorV1
| This area was generated with Dilib version V0.6.37. |  |